Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
Alistair Roddick, Alexa Wonnacott, David R. Webb, et al.
BMC Nephrology (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Colin Baigent, Jonathan Emberson, Richard Haynes, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1788-1801
Open Access | Times Cited: 611
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 16, pp. 1568-1578
Closed Access | Times Cited: 15
Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study
Anna Forbes, William Hinton, Michael Feher, et al.
EClinicalMedicine (2024) Vol. 68, pp. 102426-102426
Open Access | Times Cited: 14
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 11
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Samuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1099-1124
Open Access | Times Cited: 10
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Roko Škrabić, Marko Kumrić, Josip Vrdoljak, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2458-2458
Open Access | Times Cited: 37
Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
Chung-An Wang, Li‐Chun Lin, Jui‐Yi Chen, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Parminder K. Judge, Katherine R. Tuttle, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Open Access | Times Cited: 5
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study
Fiona A. Chapman, Vanessa Melville, Emily Godden, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Will SGLT2 Inhibitors Be Effective and Safe in Patients with Severe CKD, Dialysis, or Kidney Transplantation
Hiddo J.L. Heerspink, Stefan P. Berger, Ron T. Gansevoort
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 11, pp. 1500-1502
Open Access | Times Cited: 10
Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials
Ying Liu, Shiwen Yang, Aidou Jiang, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Chronic kidney disease management in primary care: challenges and possible developments
Heather Walker, Michael Sullivan, Bhautesh Jani, et al.
British Journal of General Practice (2025) Vol. 75, Iss. 752, pp. 104-106
Open Access
SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review
Luminița Confederat, Oana-Maria Dragostin, Mihaela-Iustina Condurache
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1960-1960
Open Access
INNOVATIVE THERAPEUTICS FOR RENOPROTECTION: WHERE WE ARE
Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
Pharmacological Reviews (2025), pp. 100060-100060
Closed Access
Emphysematous Cystitis in an Immunocompetent Patient on an SGLT2 Inhibitor
Kevin Nguyen, Durga Bista
Cureus (2025)
Open Access
Inflammatory and Cardiovascular Events in CKD: The Multi-Ethnic Study of Atherosclerosis
Gautam R. Shroff, Daniel Duprez, Evan Manning, et al.
American Journal of Kidney Diseases (2025)
Closed Access
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
Anjay Rastogi, James L. Januzzi
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2824-2824
Open Access | Times Cited: 9
Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world
Rongjing Song, Qiaoyu Hou, Xiuying Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis
Carlos Ignacio Reyes-Farias, Marcelo Reátegui-Díaz, Franco Romaní, et al.
PLoS ONE (2023) Vol. 18, Iss. 11, pp. e0295059-e0295059
Open Access | Times Cited: 6
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Marc Evans, Angharad R. Morgan, Stephen C. Bain, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 5, pp. 889-911
Open Access | Times Cited: 8
Sick day management in people with chronic kidney disease: a scoping review
Henna Duong, Wubshet Tesfaye, Connie Van, et al.
Journal of Nephrology (2022) Vol. 36, Iss. 5, pp. 1293-1306
Open Access | Times Cited: 7
Refractory IgA Nephropathy: A Challenge for Future Nephrologists
Vincenzo Di Leo, Francesca Annese, Federica Papadia, et al.
Medicina (2024) Vol. 60, Iss. 2, pp. 274-274
Open Access | Times Cited: 1
Therapeutic effects of Kangxian Yanshen formula on patients with chronic kidney disease stages 3–4: a retrospective cohort study
Aojiao Chu, Wenqian Wei, Ni Liu, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top